Physician profile
Joshua Eikenberg
NPI 1053708685
$1,115.04
in general payments reported to CMS, 2019-2025
10 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $38.77 · 2021: $71.96 · 2022: $182 · 2023: $223 · 2024: $116 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.19 | 2019-2025 | |
| Galderma Laboratories, L.P. | $118.03 | 2025 | Nemluvio |
| Pfizer INC. | $95.30 | 2023 | |
| Amgen INC. | $80.33 | 2023-2025 | Otezla, Otezla |
| Celgene Corporation | $65.10 | 2019 | |
| Strata Skin Sciences, INC. | $52.99 | 2024-2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $44.41 | 2024-2025 | Zoryve |
| Genzyme Corporation | $26.02 | 2025 | |
| Genentech USA, INC. | $24.51 | 2023 | Xolair |
| Incyte Corporation | $18.16 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Eikenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.